|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-2-1
|
|
pubmed:abstractText |
Resistance is a major challenge in the treatment of patients with gastrointestinal stromal tumors (GISTs). We investigated the mechanisms of resistance in patients with progressive GISTs with primary KIT mutations and the efficacy of the kinase inhibitor PKC412 for the inhibition of imatinib-resistant mutants.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
pubmed-author:CoolsJanJ,
pubmed-author:Debiec-RychterMariaM,
pubmed-author:DumezHerlindeH,
pubmed-author:HagemeijerAnneA,
pubmed-author:MarynenPeterP,
pubmed-author:MentensNicoleN,
pubmed-author:PrenenHansH,
pubmed-author:RoeselJohannesJ,
pubmed-author:SciotRafR,
pubmed-author:StulMichelM,
pubmed-author:Van OosteromAllanA,
pubmed-author:VranckxHildeH,
pubmed-author:WasagBartoszB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
270-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15685537-Adult,
pubmed-meshheading:15685537-Aged,
pubmed-meshheading:15685537-Antineoplastic Agents,
pubmed-meshheading:15685537-Drug Resistance, Neoplasm,
pubmed-meshheading:15685537-Exons,
pubmed-meshheading:15685537-Female,
pubmed-meshheading:15685537-Gastrointestinal Stromal Tumors,
pubmed-meshheading:15685537-Humans,
pubmed-meshheading:15685537-Male,
pubmed-meshheading:15685537-Middle Aged,
pubmed-meshheading:15685537-Mutation,
pubmed-meshheading:15685537-Piperazines,
pubmed-meshheading:15685537-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:15685537-Pyrimidines,
pubmed-meshheading:15685537-Receptor, Platelet-Derived Growth Factor alpha,
pubmed-meshheading:15685537-Staurosporine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
|
|
pubmed:affiliation |
Center for uman Genetics, Catholic University of Leuven, Leuven, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
